Acacia Research Corporation has acquired an 11.8% stake in Sensyne Health, the UK clinical AI technology company, from the LF Equity Income fund.
Clifford Press, chief executive officer, said: “We recognise the extraordinary potential of Sensyne’s business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the company’s growth.”
